
New Covid-19 Variant B.1.1.529 (Omicron) Emerges in Africa

Gilead and the NIH Appear to be Holding Back Data on LNC Remdesivir

Merck’s Covid Pill Reduces Hospitalization by About 50%

Early Use of Remdesivir Reduces Hospitalization by 87%

The Market Potential of Oral Remdesivir

Is Gilead Holding Back Data on Inhaled Remdesivir?

Gilead Set to Soar as South African COVID-19 Strain Might Resist Vaccines
